Department of Clinical Pharmacology, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, P.R. China.
Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China.
Anticancer Res. 2023 Aug;43(8):3479-3486. doi: 10.21873/anticanres.16524.
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) currently represents the third most prevalent cause of cancer-related deaths globally. HCC is typically diagnosed at advanced stages with metastasis, and has a poor outcome. In order to identify useful biomarkers for early diagnosis and develop novel therapeutic targets, it is necessary to better understand the cellular mechanisms driving HCC progression.
Public datasets were used to detect Sjögren's syndrome nuclear autoantigen-1 (SSNA1) expression in HCC. Scratch assay and transwell invasion assays were used to evaluate the migration and invasion ability of HCC cells. We explored the molecular mechanism by western blotting, viability and transfection assays.
SSNA1 was found up-regulated in human HCC tissues. SSNA1 expression increased along with HCC progression. In addition, elevated SSNA1 expression in HCC patients was closely correlated to a poor prognosis. The proliferation and apoptosis of HCC cells were unaffected by reducing SSNA1 expression. Meanwhile, STAT3/EMT axis inhibition mediated by SSNA1 depletion prevented HCC cells from migrating and invading in vitro.
SSNA1 could be used as a biomarker for HCC diagnosis and prognosis, and point the direction for the future investigation of innovative approaches to target and treat HCC.
背景/目的:肝细胞癌(HCC)目前是全球癌症相关死亡的第三大主要原因。HCC 通常在晚期转移时被诊断出来,预后较差。为了确定用于早期诊断的有用生物标志物并开发新的治疗靶点,有必要更好地了解驱动 HCC 进展的细胞机制。
使用公共数据集检测 HCC 中干燥综合征核抗原 1(SSNA1)的表达。划痕实验和 Transwell 侵袭实验用于评估 HCC 细胞的迁移和侵袭能力。我们通过 Western blot、活力和转染实验来探索分子机制。
发现 SSNA1 在人 HCC 组织中上调。SSNA1 的表达随着 HCC 的进展而增加。此外,HCC 患者中 SSNA1 表达的升高与预后不良密切相关。降低 SSNA1 表达对 HCC 细胞的增殖和凋亡没有影响。同时,SSNA1 耗竭介导的 STAT3/EMT 轴抑制可防止 HCC 细胞在体外迁移和侵袭。
SSNA1 可作为 HCC 诊断和预后的生物标志物,并为未来针对 HCC 的创新治疗方法的研究指明方向。